Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TXMD
TXMD logo

TXMD News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

TXMD News

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

Jan 08 2026NASDAQ.COM

TherapeuticsMD Swings to Profit in Q2

Aug 13 2025NASDAQ.COM

TherapeuticsMD Q2 Earnings Summary

Aug 12 2025NASDAQ.COM

Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Mar 26 2025Benzinga

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

Aug 26 2024Benzinga

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024

Aug 12 2024Business Insider

TherapeuticsMD Announces Second Quarter 2024 Financial Results

Aug 12 2024Businesswire

Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement

Jul 25 2024reuters

TXMD Events

11/12 16:14
TherapeuticsMD Announces Q3 Earnings Per Share of 0c Compared to (5c) Last Year
As of September 30, 2025, the Company's cash and cash equivalents totaled $7.1 million. The Company "continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary."
08/12 16:36
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.7 million, compared to $234 thousand in license revenue for the second quarter of 2024. The increase is primarily attributable to changes in sales of licensed products.
05/13 16:13
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.

TXMD Monitor News

No data

No data

TXMD Earnings Analysis

No Data

No Data

People Also Watch